About: Setrobuvir

An Entity of Type: person, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Setrobuvir (also known as ANA-598) was an experimental drug candidate for the treatment of hepatitis C that was discovered at Anadys Pharmaceuticals, which was acquired by Roche in 2011; Roche terminated development in July 2015. It was in Phase IIb clinical trials, used in combination with interferon and ribavirin, targeting hepatitis C patients with genotype 1. Setrobuvir works by inhibiting the hepatitis C enzyme NS5B, an RNA polymerase.

Property	Value
dbo:abstract	Setrobuvir (also known as ANA-598) was an experimental drug candidate for the treatment of hepatitis C that was discovered at Anadys Pharmaceuticals, which was acquired by Roche in 2011; Roche terminated development in July 2015. It was in Phase IIb clinical trials, used in combination with interferon and ribavirin, targeting hepatitis C patients with genotype 1. Setrobuvir works by inhibiting the hepatitis C enzyme NS5B, an RNA polymerase. (en)
dbo:alternativeName	ANA-598; ANA598 (en)
dbo:iupacName	N-(3-{(4aR,5S,8R,8aS)-1-[(4-Fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2,4a,5,6,7,8,8a-octahydro-5,8-methanoquinolin-3-yl}-1,1-dioxo-1,4-dihydro-1λ6,2,4-benzothiadiazin-7-yl)methanesulfonamide (en)
dbo:thumbnail	wiki-commons:Special:FilePath/Setrobuvir.svg?width=300
dbo:wikiPageID	33518991 (xsd:integer)
dbo:wikiPageLength	4670 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1113763467 (xsd:integer)
dbo:wikiPageWikiLink	dbc:NS5B_(polymerase)_inhibitors dbr:Ribavirin dbc:Abandoned_drugs dbr:NS5B dbr:Hepatitis_C dbc:Sulfonamides dbr:Interferon dbr:RNA_polymerase dbr:Hoffmann–La_Roche dbr:Enzyme_inhibition
dbp:imagefile	Setrobuvir.svg (en)
dbp:imagesize	200 (xsd:integer)
dbp:othernames	ANA-598; ANA598 (en)
dbp:pin	N-methanesulfonamide (en)
dbp:verifiedfields	changed (en)
dbp:verifiedrevid	461749550 (xsd:integer)
dbp:watchedfields	changed (en)
dbp:wikiPageUsesTemplate	dbt:Chembox dbt:Chembox_Hazards dbt:Chembox_Identifiers dbt:Chembox_Properties dbt:Reflist dbt:Short_description dbt:Cascite dbt:Chemspidercite dbt:Ebicite dbt:Fdacite dbt:Keggcite dbt:Stdinchicite dbt:RNA_antivirals dbt:Antiinfective-drug-stub
dcterms:subject	dbc:NS5B_(polymerase)_inhibitors dbc:Abandoned_drugs dbc:Sulfonamides
gold:hypernym	dbr:Candidate
rdf:type	owl:Thing dbo:Person dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q11173 yago:WikicatAnti-RNAVirusDrugs yago:WikicatMolecularFormulas yago:Abstraction100002137 yago:Agent114778436 yago:CausalAgent100007347 yago:Communication100033020 yago:Drug103247620 yago:Formula106816935 yago:Matter100020827 yago:Message106598915 yago:MolecularFormula106817173 yago:PhysicalEntity100001930 dbo:ChemicalCompound yago:Statement106722453 yago:Substance100020090
rdfs:comment	Setrobuvir (also known as ANA-598) was an experimental drug candidate for the treatment of hepatitis C that was discovered at Anadys Pharmaceuticals, which was acquired by Roche in 2011; Roche terminated development in July 2015. It was in Phase IIb clinical trials, used in combination with interferon and ribavirin, targeting hepatitis C patients with genotype 1. Setrobuvir works by inhibiting the hepatitis C enzyme NS5B, an RNA polymerase. (en)
rdfs:label	Setrobuvir (en)
owl:sameAs	freebase:Setrobuvir yago-res:Setrobuvir wikidata:Setrobuvir dbpedia-fa:Setrobuvir dbpedia-sh:Setrobuvir dbpedia-sr:Setrobuvir dbpedia-vi:Setrobuvir https://global.dbpedia.org/id/4v8sN
prov:wasDerivedFrom	wikipedia-en:Setrobuvir?oldid=1113763467&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Setrobuvir.svg
foaf:isPrimaryTopicOf	wikipedia-en:Setrobuvir
is dbo:wikiPageRedirects of	dbr:C25H25FN4O6S2 dbr:ANA-598 dbr:ANA598
is dbo:wikiPageWikiLink of	dbr:C25H25FN4O6S2 dbr:NS5B_(Hepacivirus) dbr:List_of_drugs:_Se–Sh dbr:ANA-598 dbr:ANA598
is foaf:primaryTopic of	wikipedia-en:Setrobuvir